Plasma Fractionation Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028
| Published: Dec 2023 | Pages: 163 | SKU: IRTNTR77166 |
Plasma Fractionation Market Forecast 2024-2028
The global plasma fractionation market size is estimated to grow by USD 10.00 billion at a CAGR of 6.09% between 2023 and 2028. The plasma industry witnesses growth with a specialized plasma therapy manufacturing facility producing immunoglobulins and albumins for therapeutic areas like respiratory diseases and liver diseases. AATD (Alpha-1-antitrypsin deficiency) and chronic obstructive pulmonary disease (COPD) are targeted, along with rare diseases and chronic disorders. Blood plasma, collected at plasma collection centers, undergoes plasma fractionation to yield essential components like anticoagulant factors and prothrombin complex.
Primary immunodeficiency conditions benefit from subcutaneous immunoglobulin (SCIG) treatments. This comprehensive approach supports patients suffering from emphysema and other lung diseases, underscoring the vital role of plasma therapy in managing diverse medical conditions.
What will be the size of the Market forecasting?
To learn more about this report, Download Report Sample
Market Segmentation by Product, Application, and Geography Analysis
Product Analysis
Immunoglobulins
The market share growth by the immunoglobulins segment will be significant during the forecast period. Immunoglobulins, also known as antibodies, play an important role in the immune system to the body's defense against infections and diseases in the global market. Immunoglobulins, particularly intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), have been essential therapeutic products derived from plasma-fractionation.
Get a glance at the market contribution of various segments Download PDF Sample
The immunoglobulins segment was valued at USD 11.52 billion in 2018. Furthermore, the rising prevalence of immunodeficiency and autoimmune disorders globally has contributed to an increased demand for immunoglobulin products. This growing patient pool has driven the production and market growth of immunoglobulins. Thus, the growing awareness of the therapeutic benefits of plasma-derived products, including immunoglobulins, has led to an increased demand for these therapies, which will boost the segment to further propel the global market during the forecast period.
Application Analysis
Immunology
Plasma-derived immunoglobulins are employed in the treatment of various autoimmune diseases like Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and type 1 diabetes. The immunomodulatory effects of immunoglobulins help to regulate the immune system and mitigate the effects of autoimmune responses. In addition, the field of immunotherapy, which involves harnessing the immune system to treat diseases such as cancer, is a rapidly evolving area. Plasma-derived immunoglobulins, along with other immunotherapeutic approaches, contribute to research and development efforts, which will drive the growth of the immunology segment in the global market during the forecast period.
Regional Analysis
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In North America, countries such as the US, Canada, and Mexico are the major markets for the market as the countries have established plasma collection centers and a culture of voluntary plasma donation, ensuring a sufficient and consistent supply of plasma for fractionation. In addition, growth in the end-uses, including by governments and non-governmental organizations (NGOs), also drives the growth of the regional market.
Additionally, with an increase in the number of hospitals and the convenience provided by them, hospitals are expanding their services related to medical care. Medical care includes surgical procedures that involve blood transfusions, thus spurring the demand for plasma-fractionation in hospitals. Hence, such factors are expected to drive market growth in this region during the forecast period.
Market Dynamics and Customer Landscape
Market growth is driven by the increasing demand for plasma-derived products like immunoglobulins and albumins, essential in therapeutic areas including respiratory diseases, AATD (Alpha-1-antitrypsin deficiency), and liver diseases. Conditions such as lung diseases, emphysema, and COPD necessitate effective treatments sourced from blood plasma. Anticoagulant factors like prothrombin complex and thrombin aid in managing rare diseases and chronic disorders.
Primary immunodeficiency disorders benefit from Subcutaneous Immunoglobulin (SCIG) therapy, obtainable from plasma collection centers. The Plasma industry, facilitated by plasma therapy manufacturing facilities, thrives on plasma fractionation, ensuring the availability of vital components for medical treatments and interventions.
Key Market Drivers
The market witnesses growth driven by the rising prevalence of lung diseases and hepatic conditions, including Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD). Plasma-derived therapies, such as immuno globulins and albumins, address these ailments. Plasma collection centers and inventories play a pivotal role in sourcing raw materials.
Anticoagulant factors like prothrombin complex and thrombin are crucial for hemostasis in conditions like Von Willebrand Disease and hemophilia. Market research and growth analysis, guided by organizations like the World Health Organization (WHO), steer advancements in plasma fractionation, catering to diverse medical needs and fostering market expansion.
Significant Market Trends
The growing elderly population and related disorders is the primary trend shaping market growth. The elderly population is more susceptible to age-related chronic diseases, including immune disorders, neurological conditions, and autoimmune diseases. Plasma-derived products, such as immunoglobulins and clotting factors, are often used in the management of these conditions. The elderly are expected to experience a higher incidence of primary immunodeficiency disorders (PIDs), where the immune system is compromised. Immunoglobulin replacement therapy derived from plasma fractionation is a common treatment for PIDs.
Furthermore, plasma-derived products are used in the management of chronic diseases that are more prevalent in older age groups. These products support patients in maintaining a better quality of life and managing the complications associated with chronic illnesses. Hence, the growing elderly population and related disorders will play a significant role in fueling the growth of the global market during the forecast period.
Major Market Challenges
Stringent government regulations regarding the safety of plasma-derived products are a challenge that affects market growth. Stringent government regulations are crucial for ensuring the safety and quality of plasma-derived products, they can pose challenges and complexities for market players. Meeting and maintaining compliance with evolving regulatory standards can be resource-intensive for vendors. This is expected to involve significant investments in infrastructure, quality control measures, and continuous monitoring.
Furthermore, achieving harmonization across different regions involves navigating diverse regulatory landscapes. Preparing for and undergoing regulatory inspections can be demanding. Non-compliance is expected to lead to regulatory actions, affecting market access and reputation. Thus, such factors are expected to impede the growth of the global market during the forecast period.
Key Market Customer Landscape
The market analysis and report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Key Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
ADMA Biologics Inc.: The company offers plasma fractionation specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
- Bharat Serums and Vaccines Ltd.
- CSL Ltd.
- Emergent BioSolutions Inc.
- GC Biopharma corp.
- Grifols SA
- Hemarus Plasma
- Intas Pharmaceuticals Ltd.
- Kamada Ltd.
- Kedrion S.p.A
- LFB SA
- Merck KGaA
- Mitsubishi Chemical Group Corp.
- Octapharma AG
- PlasmaGen BioSciences Pvt. Ltd.
- Prothya Biosolutions Netherlands BV
- Sanquin, SK Inc.
- Takeda Pharmaceutical Co. Ltd.
- Virchow Laboratories Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Market Analyst Overview
The market plays a vital role in various therapeutic areas, including respiratory diseases, liver diseases, and hemato-oncology. With a focus on treating conditions like AATD (Alpha-1-antitrypsin deficiency), emphysema, and hematological disorders, plasma-derived therapies are in high demand.
Plasma collection centers ensure a steady supply of blood plasma for fractionation, supported by regulatory authorities adhering to WHO guidelines to maintain quality and safety. Raw material suppliers play a crucial role in sourcing materials for plasma donation centers and biopharmaceutical manufacturers.
Innovations in plasma fractionation technologies, such as ethanol fractionation and automation, enhance efficiency and scalability for plasma fractionators and plasma facilities. The market landscape encompasses large companies like Baxter, mid-sized companies, and small companies, along with contract service providers catering to clinical research laboratories and academic institutes.
From diagnostic techniques like CT scanning to therapeutic interventions using recombinant factors like Kovaltry, the market continues to evolve, addressing a wide range of chronic disorders and rare diseases with precision and efficacy.
Segment Overview
The market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.
- Product Outlook
- Immunoglobulins
- Albumin
- Coagulation factor concentrates
- Protease inhibitors
- Others
- Application Outlook
- Immunology
- Neurology
- Hematology
- Critical care
- Others
- Region Outlook
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- Rest of World (ROW)
- Brazil
- Argentina
- Australia
- North America
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
163 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.09% |
|
market forecast 2024-2028 |
USD 10 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.81 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 34% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., CSL Ltd., Emergent BioSolutions Inc., GC Biopharma corp. , Grifols SA, Hemarus Plasma, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A, LFB SA, Merck KGaA, Mitsubishi Chemical Group Corp., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions Netherlands BV, Sanquin, SK Inc., Takeda Pharmaceutical Co. Ltd., and Virchow Laboratories Ltd. |
|
Market dynamics |
Parent market trends and analysis, market growth and forecasting inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the market between 2024 and 2028
- Precise estimation of the market size and its contribution to the market market forecast on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies' position and classification
- Accurate predictions about upcoming trends, market growth and trends and changes in consumer behavior
- The market growth analysis and trends across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of market companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2023
- 3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global plasma fractionation market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global plasma fractionation market 2018 - 2022 ($ billion)
- 4.2 Product Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
- 4.3 Application Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Application Segment 2018 - 2022 ($ billion)
- 4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
- 4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
- 6.1 Market segments
- Exhibit 30: Chart on Product - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
- 6.2 Comparison by Product
- Exhibit 32: Chart on Comparison by Product
- Exhibit 33: Data Table on Comparison by Product
- 6.3 Immunoglobulins - Market size and forecast 2023-2028
- Exhibit 34: Chart on Immunoglobulins - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Immunoglobulins - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Immunoglobulins - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Immunoglobulins - Year-over-year growth 2023-2028 (%)
- 6.4 Albumin - Market size and forecast 2023-2028
- Exhibit 38: Chart on Albumin - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Albumin - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Albumin - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Albumin - Year-over-year growth 2023-2028 (%)
- 6.5 Coagulation factor concentrates - Market size and forecast 2023-2028
- Exhibit 42: Chart on Coagulation factor concentrates - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Coagulation factor concentrates - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Coagulation factor concentrates - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Coagulation factor concentrates - Year-over-year growth 2023-2028 (%)
- 6.6 Protease inhibitors - Market size and forecast 2023-2028
- Exhibit 46: Chart on Protease inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 47: Data Table on Protease inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 48: Chart on Protease inhibitors - Year-over-year growth 2023-2028 (%)
- Exhibit 49: Data Table on Protease inhibitors - Year-over-year growth 2023-2028 (%)
- 6.7 Others - Market size and forecast 2023-2028
- Exhibit 50: Chart on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 51: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 52: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 53: Data Table on Others - Year-over-year growth 2023-2028 (%)
- 6.8 Market opportunity by Product
- Exhibit 54: Market opportunity by Product ($ billion)
- Exhibit 55: Data Table on Market opportunity by Product ($ billion)
7 Market Segmentation by Application
- 7.1 Market segments
- Exhibit 56: Chart on Application - Market share 2023-2028 (%)
- Exhibit 57: Data Table on Application - Market share 2023-2028 (%)
- 7.2 Comparison by Application
- Exhibit 58: Chart on Comparison by Application
- Exhibit 59: Data Table on Comparison by Application
- 7.3 Immunology - Market size and forecast 2023-2028
- Exhibit 60: Chart on Immunology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 61: Data Table on Immunology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 62: Chart on Immunology - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Immunology - Year-over-year growth 2023-2028 (%)
- 7.4 Neurology - Market size and forecast 2023-2028
- Exhibit 64: Chart on Neurology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 65: Data Table on Neurology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 66: Chart on Neurology - Year-over-year growth 2023-2028 (%)
- Exhibit 67: Data Table on Neurology - Year-over-year growth 2023-2028 (%)
- 7.5 Hematology - Market size and forecast 2023-2028
- Exhibit 68: Chart on Hematology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 69: Data Table on Hematology - Market size and forecast 2023-2028 ($ billion)
- Exhibit 70: Chart on Hematology - Year-over-year growth 2023-2028 (%)
- Exhibit 71: Data Table on Hematology - Year-over-year growth 2023-2028 (%)
- 7.6 Critical care - Market size and forecast 2023-2028
- Exhibit 72: Chart on Critical care - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Data Table on Critical care - Market size and forecast 2023-2028 ($ billion)
- Exhibit 74: Chart on Critical care - Year-over-year growth 2023-2028 (%)
- Exhibit 75: Data Table on Critical care - Year-over-year growth 2023-2028 (%)
- 7.7 Others - Market size and forecast 2023-2028
- Exhibit 76: Chart on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 78: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 79: Data Table on Others - Year-over-year growth 2023-2028 (%)
- 7.8 Market opportunity by Application
- Exhibit 80: Market opportunity by Application ($ billion)
- Exhibit 81: Data Table on Market opportunity by Application ($ billion)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 82: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 83: Chart on Market share by geography 2023-2028 (%)
- Exhibit 84: Data Table on Market share by geography 2023-2028 (%)
- 9.2 Geographic comparison
- Exhibit 85: Chart on Geographic comparison
- Exhibit 86: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Exhibit 87: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Exhibit 91: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Exhibit 95: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 99: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Exhibit 103: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 104: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 105: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 China - Market size and forecast 2023-2028
- Exhibit 107: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 108: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 109: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 110: Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.9 Germany - Market size and forecast 2023-2028
- Exhibit 111: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 112: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 113: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 114: Data Table on Germany - Year-over-year growth 2023-2028 (%)
- 9.10 UK - Market size and forecast 2023-2028
- Exhibit 115: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 116: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 117: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 118: Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.11 Japan - Market size and forecast 2023-2028
- Exhibit 119: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 120: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 121: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 122: Data Table on Japan - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity by geography
- Exhibit 123: Market opportunity by geography ($ billion)
- Exhibit 124: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 125: Impact of drivers and challenges in 2023 and 2028
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 126: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 127: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 128: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 129: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 130: Matrix on vendor position and classification
- 12.3 ADMA Biologics Inc.
- Exhibit 131: ADMA Biologics Inc. - Overview
- Exhibit 132: ADMA Biologics Inc. - Business segments
- Exhibit 133: ADMA Biologics Inc. - Key offerings
- Exhibit 134: ADMA Biologics Inc. - Segment focus
- 12.4 Bharat Serums and Vaccines Ltd.
- Exhibit 135: Bharat Serums and Vaccines Ltd. - Overview
- Exhibit 136: Bharat Serums and Vaccines Ltd. - Product / Service
- Exhibit 137: Bharat Serums and Vaccines Ltd. - Key offerings
- 12.5 CSL Ltd.
- Exhibit 138: CSL Ltd. - Overview
- Exhibit 139: CSL Ltd. - Business segments
- Exhibit 140: CSL Ltd. - Key offerings
- Exhibit 141: CSL Ltd. - Segment focus
- 12.6 Emergent BioSolutions Inc.
- Exhibit 142: Emergent BioSolutions Inc. - Overview
- Exhibit 143: Emergent BioSolutions Inc. - Product / Service
- Exhibit 144: Emergent BioSolutions Inc. - Key news
- Exhibit 145: Emergent BioSolutions Inc. - Key offerings
- 12.7 GC Biopharma corp.
- Exhibit 146: GC Biopharma corp. - Overview
- Exhibit 147: GC Biopharma corp. - Product / Service
- Exhibit 148: GC Biopharma corp. - Key offerings
- 12.8 Grifols SA
- Exhibit 149: Grifols SA - Overview
- Exhibit 150: Grifols SA - Business segments
- Exhibit 151: Grifols SA - Key offerings
- Exhibit 152: Grifols SA - Segment focus
- 12.9 Intas Pharmaceuticals Ltd.
- Exhibit 153: Intas Pharmaceuticals Ltd. - Overview
- Exhibit 154: Intas Pharmaceuticals Ltd. - Product / Service
- Exhibit 155: Intas Pharmaceuticals Ltd. - Key offerings
- 12.10 Kedrion S.p.A
- Exhibit 156: Kedrion S.p.A - Overview
- Exhibit 157: Kedrion S.p.A - Product / Service
- Exhibit 158: Kedrion S.p.A - Key offerings
- 12.11 LFB SA
- Exhibit 159: LFB SA - Overview
- Exhibit 160: LFB SA - Product / Service
- Exhibit 161: LFB SA - Key offerings
- 12.12 Merck KGaA
- Exhibit 162: Merck KGaA - Overview
- Exhibit 163: Merck KGaA - Business segments
- Exhibit 164: Merck KGaA - Key news
- Exhibit 165: Merck KGaA - Key offerings
- Exhibit 166: Merck KGaA - Segment focus
- 12.13 Mitsubishi Chemical Group Corp.
- Exhibit 167: Mitsubishi Chemical Group Corp. - Overview
- Exhibit 168: Mitsubishi Chemical Group Corp. - Business segments
- Exhibit 169: Mitsubishi Chemical Group Corp. - Key offerings
- Exhibit 170: Mitsubishi Chemical Group Corp. - Segment focus
- 12.14 Octapharma AG
- Exhibit 171: Octapharma AG - Overview
- Exhibit 172: Octapharma AG - Product / Service
- Exhibit 173: Octapharma AG - Key offerings
- 12.15 Sanquin
- Exhibit 174: Sanquin - Overview
- Exhibit 175: Sanquin - Product / Service
- Exhibit 176: Sanquin - Key offerings
- 12.16 SK Inc.
- Exhibit 177: SK Inc. - Overview
- Exhibit 178: SK Inc. - Product / Service
- Exhibit 179: SK Inc. - Key offerings
- 12.17 Takeda Pharmaceutical Co. Ltd.
- Exhibit 180: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 181: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 182: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 183: Takeda Pharmaceutical Co. Ltd. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 184: Inclusions checklist
- Exhibit 185: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 186: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 187: Research methodology
- Exhibit 188: Validation techniques employed for market sizing
- Exhibit 189: Information sources
- 13.5 List of abbreviations
- Exhibit 190: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
plasma fractionation market market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis